摘要
背景:T细胞急性淋巴细胞白血病(T-ALL)是一种骨髓和淋巴母细胞疾病,主要表现在T细胞免疫表型上。 TALL 患者的诊断显示外周血管中的大肿瘤和白血病细胞的负担经常渗入中枢神经系统。 目的:化疗被认为是该疾病的主要治疗方式,但最近对该疾病分子理解的进展,包括 NOTCH1 信号传导,可以提供一些替代方案。在大多数 T-ALL 中,NOTCH 信号在 NOTCH1 处发生非调节突变。 γ-分泌酶 (GS) 在阻断 NOTCH 受体的蛋白水解激活中起关键作用,这可能成为治疗此类白血病的新靶向疗法。本研究主要旨在概述 γ-分泌酶抑制剂通过 NOTCH 信号传导在 TALL 中的作用。 结果:GSI(γ-分泌酶抑制剂)在大多数 T-ALL 细胞系中的作用与 NOTCH 信号的靶向通路有关。然而,由于多种因素,包括 NOTCH 通路活性的基因表达,NOTCH1 的突变不能作为 γ-分泌酶抑制剂敏感性的预测因子。因此,尽管这种方法在 NOTCH-1 激活的 T-ALL 中取得了有希望的结果,但并非所有患有这种疾病的患者都会有反应。 结论:单一疗法很少能取得针对癌细胞的长期治疗成功,甚至针对研究性通路(如 NOTCH)也可能需要联合方案。最终,这些新治疗药物的优化使用可能成为我们寻找有效“个体化药物”的下一个工具。
关键词: γ-分泌酶抑制剂、T-ALL、NOTCH1、突变、癌症、靶向治疗。
Current Drug Targets
Title:Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Volume: 22 Issue: 15
关键词: γ-分泌酶抑制剂、T-ALL、NOTCH1、突变、癌症、靶向治疗。
摘要:
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a diseased condition of bone marrow and lymphoblast, mainly expressed on T-cell immune phenotype. Diagnosis of TALL patients shows the burden of a large tumour and leukemia cells in the peripheral blood vessel which often infiltrates into the central nervous system.
Objective: Chemotherapy is considered the primary mode of treatment for this disease, but recent advancements in the molecular understanding of the disease, including NOTCH1 signaling, could offer some alternatives. NOTCH signaling undergoes a non-regulated mutation at NOTCH1 in most T-ALL. Gamma-secretase (GS) plays a key role in blocking of proteolytic activation of NOTCH receptors, which could potentially be a new targeted therapy for this type of leukaemia. This study mainly aims to outline the role of γ-secretase inhibitors via NOTCH signaling in TALL.
Results: The role of GSI (γ-secretase inhibitor) in most T-ALL cell lines has been linked to the targeting pathway of NOTCH signaling. Mutation at NOTCH1 has however not served as a predictor of γ-secretase inhibitor sensitivity because of several factors, including gene expression of NOTCH pathway activity. Therefore, despite the promising outcome of this approach in NOTCH-1 activated T-ALL, not all patients with this condition are expected to respond.
Conclusion: Long-term therapeutic success against cancerous cells is rarely achieved with monotherapy, and even targeting investigational pathways such as NOTCH may require a combination regimen. Ultimately, the optimised use of these new therapeutic agents may become the next tool in our search for an effective ‘individualized medicine’.
Export Options
About this article
Cite this article as:
Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia, Current Drug Targets 2021; 22 (15) . https://dx.doi.org/10.2174/1389450122666210203192752
DOI https://dx.doi.org/10.2174/1389450122666210203192752 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Sojourn of Polymeric Micelles for Effective Brain Drug Delivery
System
Current Drug Delivery The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Editorial [Hot Topic: Targeted Therapies in Oncology (Guest Editor: Monica M. Mita)]
Current Drug Targets Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms
Current Drug Targets Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Antiangiogenic Gene Therapy in Cancer
Current Genomics Anti-cancer Therapies in High Grade Gliomas
Current Proteomics Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer
Current Genomics